<DOC>
	<DOCNO>NCT02073149</DOCNO>
	<brief_summary>This study determine whether haemoglobin response daily home fortification 30 day 3mg iron NaFeEDTA non-inferior 12.5 mg iron encapsulate ferrous fumarate .</brief_summary>
	<brief_title>Safe Efficacious Iron Children Kenya</brief_title>
	<detailed_description>Background : Fortification local complementary food supplementation micronutrient powder include iron show prevent anaemia . Iron cause complaint ( diarrhoea , constipation , etc . ) relate oxidative stress intestine , however , dose conventionally use daily supplementation , iron increase rate malaria diarrhoea . A low dose iron ( 3mg/day ) NaFEEDTA reduce adverse effect whilst similar superior efficacy improve iron status conventional-dose iron ( 12.5mg ) ferrous salt . Objective : The primary aim compare daily home fortification 3mg iron NaFeEDTA versus 12.5 mg iron encapsulate ferrous fumarate regard haemoglobin concentration end 30-day fortification period . Methods : Rural child age 12-36 month ( n=324 ) receive albendazole praziquantel helminth infection , preventive chemotherapy malaria dihydroartemisinin-piperaquine . They subsequently randomise daily home fortification 30 day sachet contain either ) 3 mg iron NaFeEDTA ; b ) 12.5 mg iron encapsulate ferrous fumarate ; c ) placebo . Parents guardian instructed mix content sachet solid semi-solid , ready-prepared food . Adherence assess electronic monitoring time-recording device cap dispense bottle contain sachet . At end 30-day fortification period , venous blood sample collected measure indicator iron status inflammation . Children receive iron continue follow maximum 120 day randomisation estimate time point ≥10 % child develop severe anaemia ( haemoglobin concentration &lt; 70 g/L ) .</detailed_description>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferrous fumarate</mesh_term>
	<mesh_term>Fe ( III ) -EDTA</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Aged 12−36 month ; 2 . Residing study area ; 3 . Planning area duration intervention followup ; 4 . Study protocol accept informed consent give least one parent guardian 1 . Known report allergy dihydroartemisinin , piperaquine , benzimidazole drug praziquantel ; 2 . A sibling household already randomise intervention ; 3 . Severely malnourished ( weightforheight zscore &lt; ‒3 SD ) ( ethical reason ) ; 4 . Presence fever ( axillary temperature ≥ 37.5 ºC ) ( avoid inflammationinduced effect iron status marker ) ; 5 . Presence report suspected systemic disorder ( e.g . HIV infection , sickle cell disease ) ( avoid inflammationinduced effect iron status marker avoid attrition ) ; 6 . Missed one several dose 3day course dihydroartemisininpiperaquine ( ensure participant protect malaria duration iron intervention ) ; 7 . No blood sample collect , blood volume collect &lt; 5 mL ; 8 . Haemoglobin concentration &lt; 70 g/L ( prevent severe anaemia ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Iron</keyword>
	<keyword>Anemia</keyword>
	<keyword>Sodium Fe ( III ) -ethylenediaminetetraacetic acid ( NaFeEDTA )</keyword>
	<keyword>Ferrous compound</keyword>
	<keyword>Child , preschool</keyword>
	<keyword>Kenya</keyword>
</DOC>